Welcome to our dedicated page for Perspective Therapeutics news (Ticker: CATX), a resource for investors and traders seeking the latest updates and insights on Perspective Therapeutics stock.
Perspective Therapeutics, Inc. (NYSE American: CATX) is a radiopharmaceutical development company focused on 212Pb-based theranostic treatments and imaging for cancer. The CATX news page on Stock Titan aggregates company announcements, clinical data updates, conference presentations, financial disclosures, and other material events drawn from press releases and SEC filings.
According to recent communications, Perspective regularly reports interim results from its Phase 1/2a trials of [212Pb]VMT-α-NET in SSTR2-positive neuroendocrine tumors, VMT01 in melanoma patients with MC1R-positive imaging scans, and PSV359 in FAP-α-positive solid tumors. News items often summarize safety findings, investigator-assessed anti-tumor activity, and progress across dose cohorts, along with plans for data presentations at major meetings such as ASCO, ASCO-GI, ESMO, NANETS, and AACR-NCI-EORTC conferences.
Investors and observers can also find updates on corporate presentations, participation in healthcare and biopharma conferences, and periodic business highlights tied to quarterly financial results. Form 8-K filings referenced in the news flow include earnings releases, updated corporate slide decks, and information about executive appointments and employment agreements.
For anyone tracking CATX, this news feed provides a centralized view of Perspective’s clinical development trajectory, manufacturing expansion efforts around its proprietary 212Pb generator, and key corporate developments. Users interested in radiopharmaceutical and oncology catalysts may wish to revisit this page around major medical congresses, scheduled earnings dates, and company-announced business updates.
Perspective Therapeutics (NYSE AMERICAN: CATX) announced its inclusion in the Russell 3000 Index, effective July 1, 2024. This annual reconstitution captures the 4,000 largest US stocks by market capitalization as of April 30. Perspective's inclusion also means potential membership in the Russell 1000 or Russell 2000 Index. CEO Thijs Spoor highlighted the company's recent clinical and corporate milestones as key factors for this recognition. The Russell indexes, used by investment managers for index funds and benchmarks, have around $10.5 trillion in assets as of December 2023.
Perspective Therapeutics (NYSE AMERICAN: CATX) has announced a 1-for-10 reverse stock split, effective June 14, 2024, at 4:01 p.m. Eastern time. Trading on a split-adjusted basis will begin on June 17, 2024. The reverse split will reduce the number of outstanding shares from approximately 674.3 million to 67.4 million. Stockholders approved the proposal at the annual meeting on May 31, 2024. The reverse split will not change the total number of authorized shares or the par values of the company's stock. Stockholders will receive cash for any fractional shares. All outstanding options and warrants will be adjusted accordingly.
Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company, announced six updates at the SNMMI 2024 Annual Meeting. Key updates include:
1. [212Pb]VMT-α-NET Phase I/IIa trial targeting neuroendocrine tumors showed a favorable safety profile.
2. Optimal imaging time for [203Pb]-VMT-α-NET was determined to be 4 hours post-injection.
3. First-in-human use of [212Pb]VMT-α-NET in India showed an encouraging tumor response, with a median PFS of 16.4 months.
4. Personalized dosimetry for [203Pb]VMT-α-NET and corresponding treatment plans for [212Pb]VMT-α-NET were discussed.
5. Pre-clinical studies on [212Pb]VMT01 for melanoma showed strong anti-tumor effects when combined with immune checkpoint inhibitors.
6. Novel peptide [203/212Pb]-PSV-359 showed promising anti-tumor activity in preclinical models.
Perspective Therapeutics (NYSE AMERICAN: CATX) announced the pricing of an $80 million underwritten offering of common stock and pre-funded warrants. The offering includes 51,515,880 common shares priced at $1.51 each and pre-funded warrants priced at $1.509 per warrant. The offering is expected to close by May 29, 2024, pending customary closing conditions. BofA Securities, Oppenheimer & Co., and RBC Capital Markets are joint book-runners, with B. Riley Securities as co-manager. Proceeds will support clinical development, manufacturing expansion, and general corporate purposes.
Perspective Therapeutics (NYSE AMERICAN: CATX) will present at the SNMMI Annual Meeting 2024 in Toronto from June 8-11. The company will showcase its clinical and preclinical research, including updates from its Phase 1/2a dose escalation study of [212Pb]VMT-α-NET for neuroendocrine tumors, and preclinical progress on [212Pb]VMT01 for melanoma. Highlights include pooled data from Phase 0 imaging studies and dosimetry evaluations. Additional presentations will cover [212Pb]VMT01 combined with immune checkpoint inhibitors, and [203/212Pb]-PSV-359 targeting FAP in tumor lesions. CEO Thijs Spoor emphasized the company's commitment to advancing cancer treatments.
Perspective Therapeutics (NYSE AMERICAN: CATX) reported fiscal Q1 2024 results and recent business highlights. The company raised $177.2 million through financing and an additional $49.5 million via an ATM agreement. Research and development expenses increased by 127%, while general and administrative expenses decreased by 12%. The net loss for the quarter was $12.3 million, or $0.02 per share, compared to $0.4 million the previous year. The company initiated dosing in its VMT-α-NET and VMT01 clinical trials and entered a collaboration with Bristol Myers Squibb. Perspective's current cash position is $180.6 million, with sufficient funding expected through Q1 2026.
Perspective Therapeutics, Inc. announced participation in various investor conferences in May 2024. The company will showcase advanced cancer treatment applications, providing opportunities for investors to engage with the senior leadership team. Events include discussions on the radiopharmaceutical industry's evolving landscape and fireside chats at prominent conferences.
Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX) will report its first quarter 2024 financial results on May 15, 2024, showcasing its advancements in radiopharmaceutical treatments for various cancers.
Perspective Therapeutics, Inc. (CATX) has been selected by the FDA to participate in the CDRP program for the development of [212Pb]VMT‐α‐NET for the treatment of patients with NETs. The program aims to expedite the CMC development of novel products under IND applications to provide earlier patient access. The investigational product is intended for PRRT-naïve patients with SSTR2-positive unresectable or metastatic NETs and has been granted Fast Track Designation by the FDA based on preclinical data.
Summary not available.